

Rev 1: September 2018

FSN Ref: FSN_01_2022_DK FSCA Ref: FSCA_01_2022

Date: 26-04-2022

<u>Urgent Field Safety Notice</u> <u>Volumed Set – APTPK0J-PP</u>

For Attention of*:

Contact details of local representative (name, e-mail, telephone, address etc.)*

Timik Group AB, Box 426, SE-19124 Sollentuna, Sweden. Contact: mats.nilsson@timikgroup.com



Rev 1: September 2018

FSN Ref: FSN_01_2022_DK FSCA Ref: FSCA_01_2022

<u>Urgent Field Safety Notice (FSN)</u> <u>Volumed Set – APTPK0J-PP</u>

Tube disconnection from drip chamber - blood leakage

	1. Information on Affected Devices*			
1	1. Device Type(s)*			
	Volumed Transfusion Set, Non-Vented, Polypropylene, 235cm, Robson Clamp and Male			
	Luer Lock			
1	2. Commercial name(s)			
	Volumed ® Set			
1	Unique Device Identifier(s) (UDI-DI)			
1	4. Primary clinical purpose of device(s)*			
	Set for blood Transfusion			
1	5. Device Model/Catalogue/part number(s)*			
	APTPK0J-PP			
1	6. Software version			
	n.a.			
1	7. Affected serial or lot number range			
	21PH088			
	21PH202			
	21PH210			
1	8. Associated devices			
'				
	n.a.			

	2 Reason for Field Safety Corrective Action (FSCA)*			
2	Description of the product problem*			
	End user experienced case of disconnection between the drip chamber and the tubing.			
2	2. Hazard giving rise to the FSCA*			
	Blood can come into contact with the skin of healthcare workers and patients. Failure to			
	perform the transfusion. Delay in the transfusion.			
2	3. Probability of problem arising			
	Low			
2	4. Predicted risk to patient/users			
	Blood contamination			
2	Further information to help characterise the problem			
	none			
2	6. Background on Issue			
	Internal analysis has shown that the connection between tube and drip chamber may			
	come loose during normal usage due to impredictable tensile stress from user			
	manipulation.			
2	7. Other information relevant to FSCA			
	none			

Rev 1: September 2018
FSN Ref: FSN_01_2022_DK
FSCA Ref: FSCA_01_2022

		3. Type of Action to mitigate the risk*		
3.	1.	Action To Be Taken by the User*		
		□ Quar □	antine Device ⊠ Return De	evice Destroy Device
		☐ On-site device modification/inspection		
		☐ Follow patient management recommendations		
		☐ Take note of amendment/r	einforcement of Instructions For Us	se (IFU)
		☐ Other ☐ None	9	
		Provide further details of the action(s) identified.		
3.	2.	By when should the action be completed?	immediately	
		action be completed.		
3.	3.	Particular considerations for:		
		Is follow-up of patients or r	eview of patients' previous resu	Its recommended?
		NO		
			ive and therefore did not becom	
2	1		nded use, i.e. to perform the tra	
3.	4.	Is customer Reply Require yes, form attached specifyir		Yes
3.		Action Being Taken by		
٥.	0.	Addon Being Taken by	the Manarastarer	
		□ Product Removal □	☐ On-site device modification/inspe	ection
			☐ IFU or labelling change	
		⊠ Other □	□ None	
		modification of the components of the products in order to guarantee a more secure connection		
3	6.	By when should the	Specify where critical to patie	nt/end user safety
		action be completed?		
3.	7.	Is the FSN required to be of /lay user?	communicated to the patient	No
3	8.	If yes, has manufacturer provided additional information suitable for the patient/lay		
		user in a patient/lay or non-professional user information letter/sheet?		
		Choose an item. Choose	an item.	

	4. General Information*	
4.	1. FSN Type*	New
4.	For updated FSN, reference number and date of previous FSN	Provide reference and date of previous FSN if relevant
4.	3. For Updated FSN, key new information as follows:	

Rev 1: September 2018

FSN Ref: FSN_01_2022_DK FSCA Ref: FSCA_01_2022

	Summarise any key difference in devices affected and/or action to be taken.		
4.	4. Further advice or information already expected in follow-up FSN? *	No	
If follow-up FSN expected, what is the further advice expected Eg patient management, device modifications etc		the further advice expected to relate to:	
		ications etc	
4	6. Anticipated timescale for follow- up FSN	For provision of updated advice.	
4.	7. Manufacturer information		
	(For contact details of local representative refer to page 1 of this FSN)		
	a. Company Name	Phoenix srl	
	b. Address	Via Leonardo da Vinci 55, san Felice sul Panaro (MO), Italy	
	c. Website address	Only necessary if not evident on letter-head.	
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. * YES		
4.	9. List of attachments/appendices:	If extensive consider providing web-link instead.	
4.	10. Name/Signature	Federico Prandini	
		Felis Polis.	

Transmission of this Field Safety Notice

This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)

Please transfer this notice to other organisations on which this action has an impact. (As appropriate)

Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback..*

Note: Fields indicated by * are considered necessary for all FSNs. Others are optional.